Two studies published this week have reported new insights into the role of the nervous system in tumors outside of the brain. Researchers at the Shanghai Jiao Tong University School of Medicine have identified a role for pain-sensing neurons in helping oral carcinomas cope with nutrient starvation, and that this interaction could be blocked by the calcitonin gene-related peptide (CGRP)-targeting migraine drug Nurtec ODT (rimegepant; Biohaven Pharmaceutical Holding Co. Ltd.).
Elevatebio LLC and Affini-T Therapeutics Inc. have entered into a partnership to advance Affini-T's engineered T-cell therapies focused on KRAS, an oncogenic driver mutation in solid tumor cancers.
Heptares Therapeutics Ltd. has presented G protein-coupled receptor GPR35 agonists reported to be useful for the treatment of acute and chronic pain, gastrointestinal and lung diseases.
Integral Biosciences Pvt. Ltd. (IBS) has synthesized oxysterols receptor LXR-β (LXRB) agonists reported to be useful for the treatment of cancer, inflammation and Alzheimer's disease.
Chemocentryx Inc. has divulged azetidinyl-acetamides acting as atypical chemokine receptor 3 (ACKR3) antagonists reported to be useful for the treatment of cancer and inflammatory disorders.
Rhabdomyosarcoma (RMS) occurs in 3% of all pediatric cancers. Aberrant Hedgehog (Hh) activation can be ligand-dependent or -independent, but current clinical Hh inhibitors targeting SMO are effective only for ligand-independent tumors. Researchers at Vall d’Hebron Institut de Recerca, Barcelona, Spain, developed a targeted therapeutic for Hh ligand-dependent tumors.
AZD-4820 was evaluated in a cell viability assay performed in 30 human cancer cell lines, defining 12 different types of cancer, and testing a dose-range of multiplicity of infection (MOI); potent oncolytic activity was observed with EC50 values of <0.1 MOI in nearly all of the tested cells.
Bonum Therapeutics Inc., a spinout of Good Therapeutics Inc., which Roche Holding AG acquired in August, has announced a US$93 million series A financing. Bonum is developing new therapies based on the proprietary platform of allosterically regulated, conditionally active therapeutics developed by Good Therapeutics. The core platform makes possible the engineering and development of a wide range of medicines.
Circulating tumor cells (CTCs) transit through the bloodstream and they exhibit heterogeneity in their expression of epithelial and mesenchymal marker proteins, including the cadherin proteins. Based on these findings, researchers from Massachusetts General Hospital and Harvard Medical School evaluated the potential of the dual anti-cadherin antibody, 23C6, in targeting CTC-dependent blood-borne metastasis.
At the recent Society for Immunotherapy of Cancer meeting, researchers from Dong-A ST Co. Ltd. presented preclinical data for the novel small-molecule general control nonderepressible 2 (GCN2) inhibitor, DA-4507, being developed for the treatment of cancer.
RSS
